Merck Millipore acquires rights for Biotest microbiology products
Merck Millipore now has exclusive rights to sell Biotest microbiology products in Australia and New Zealand.
In 2011, Merck Millipore acquired German company Biotest, an innovative industrial microbiology company with capabilities in ready-to-use media and hygiene monitoring. Its products are targeted at the pharmaceutical and food and beverage segments.
Biotest’s microbiology products, previously marketed by either of their two trading companies, Heipha and Hycon, are now exclusively available through Merck Millipore. Technical support for the products is also offered.
Billion-dollar deal for UQ's molecular clamp vaccine tech
Sanofi has entered into an agreement to acquire Vicebio, a biotech company formed in 2018 to...
Director of scandal-ridden Forensic Science Queensland resigns
Dr Linzi Wilson-Wilde resigned from her position one month after being suspended by Queensland...
$492m pathology hub coming to Westmead Health Precinct
The NSW Health Pathology Statewide Hub will be delivered to Westmead Health Precinct, as part of...
